Mohamed Noureldin1,2, Peter D R Higgins1, Shail M Govani3, Shirley Cohen-Mekelburg1, Brooke C Kenney4,5, Ryan W Stidham1, Jennifer F Waljee4,5, Akbar K Waljee1,2. 1. Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan. 2. Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan. 3. Department of Internal Medicine, Division of Gastroenterology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas. 4. Department of Surgery, University of Michigan, Ann Arbor, Michigan. 5. Michigan Opioid Prescribing Engagement Network, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: Opioids are commonly prescribed to manage pain associated with inflammatory bowel disease (IBD). It is unknown what percentage of patients develop new persistent opioid use following a steroid-treated IBD flare. AIM: To identify the incidence and the predictors of new persistent opioid use following an IBD flare. METHODS: We used a national insurance claim dataset to identify patients with IBD who received an opioid medication around the time of a corticosteroid-treated IBD flare. Patients were stratified as previously opioid naïve, intermittent users, or chronic users. The incidence of persistent opioid use among the opioid-naïve cohort was evaluated along with associated predictors. RESULTS: We identified 15 119 IBD patients who received opioids around the time of a flare. 5411 (35.8%) were opioid-naïve patients of which 35.0% developed persistent opioid use after the flare. Factors associated with new persistent opioid use include a history of depression (hazard ratio [HR] 1.29, 95% confidence interval [CI] 1.13-1.47), substance abuse (HR 1.36, 95% CI 1.2-1.54), chronic obstructive pulmonary disease (COPD) (HR 1.17, 95% CI 1.04-1.3), as well as, Crohn's disease (HR 1.26, 95% CI 1.14-1.4) or indeterminate colitis (HR 1.6, 95% CI 1.36-1.88). CONCLUSIONS: New persistent opioid use is common in IBD patients who experience a flare, especially among those with mental health disorders, COPD, and Crohn's disease or indeterminate colitis. These findings can be helpful in risk-stratifying patients when choosing an acute pain therapy and providing counselling before choosing to prescribe opioids to opioid-naïve patients experiencing an IBD flare.
BACKGROUND: Opioids are commonly prescribed to manage pain associated with inflammatory bowel disease (IBD). It is unknown what percentage of patients develop new persistent opioid use following a steroid-treated IBD flare. AIM: To identify the incidence and the predictors of new persistent opioid use following an IBD flare. METHODS: We used a national insurance claim dataset to identify patients with IBD who received an opioid medication around the time of a corticosteroid-treated IBD flare. Patients were stratified as previously opioid naïve, intermittent users, or chronic users. The incidence of persistent opioid use among the opioid-naïve cohort was evaluated along with associated predictors. RESULTS: We identified 15 119 IBDpatients who received opioids around the time of a flare. 5411 (35.8%) were opioid-naïve patients of which 35.0% developed persistent opioid use after the flare. Factors associated with new persistent opioid use include a history of depression (hazard ratio [HR] 1.29, 95% confidence interval [CI] 1.13-1.47), substance abuse (HR 1.36, 95% CI 1.2-1.54), chronic obstructive pulmonary disease (COPD) (HR 1.17, 95% CI 1.04-1.3), as well as, Crohn's disease (HR 1.26, 95% CI 1.14-1.4) or indeterminate colitis (HR 1.6, 95% CI 1.36-1.88). CONCLUSIONS: New persistent opioid use is common in IBDpatients who experience a flare, especially among those with mental health disorders, COPD, and Crohn's disease or indeterminate colitis. These findings can be helpful in risk-stratifying patients when choosing an acute pain therapy and providing counselling before choosing to prescribe opioids to opioid-naïve patients experiencing an IBD flare.
Authors: Chad M Brummett; Jennifer F Waljee; Jenna Goesling; Stephanie Moser; Paul Lin; Michael J Englesbe; Amy S B Bohnert; Sachin Kheterpal; Brahmajee K Nallamothu Journal: JAMA Surg Date: 2017-06-21 Impact factor: 14.766
Authors: Seth D Crockett; Richard A Hansen; Til Stürmer; Robin Schectman; Jane Darter; Robert S Sandler; Michael D Kappelman Journal: Inflamm Bowel Dis Date: 2011-08-08 Impact factor: 5.325
Authors: Anava A Wren; Rachel Bensen; Lindsay Sceats; Melody Dehghan; Helen Yu; Jessie J Wong; Donna MacIsaac; Zachary M Sellers; Cindy Kin; K T Park Journal: Inflamm Bowel Dis Date: 2018-09-15 Impact factor: 7.290
Authors: Helmut Grasberger; Mohamed Noureldin; Timothy D Kao; Jeremy Adler; Joyce M Lee; Shrinivas Bishu; Mohamad El-Zaatari; John Y Kao; Akbar K Waljee Journal: Sci Rep Date: 2018-07-05 Impact factor: 4.379
Authors: Taryn E Hassinger; Elizabeth D Krebs; Florence E Turrentine; Robert H Thiele; Bethany M Sarosiek; Sook C Hoang; Charles M Friel; Traci L Hedrick Journal: Surg Endosc Date: 2020-05-11 Impact factor: 4.584
Authors: Mohamed Noureldin; Shirley Cohen-Mekelburg; Asadullah Mahmood; Ryan Stidham; Peter D R Higgins; Shail Govani; Amar R Deshpande; Akbar K Waljee Journal: Inflamm Bowel Dis Date: 2021-03-15 Impact factor: 5.325
Authors: Jeffrey A Berinstein; Shirley A Cohen-Mekelburg; Calen A Steiner; Megan McLeod; Mohamed Noureldin; John I Allen; Jeffrey T Kullgren; Akbar K Waljee; Peter D R Higgins Journal: Inflamm Bowel Dis Date: 2021-05-17 Impact factor: 7.290
Authors: Antonina Mikocka-Walus; Wayne Massuger; Simon R Knowles; Gregory T Moore; Stephanie Buckton; William Connell; Paul Pavli; Leanne Raven; Jane M Andrews Journal: JGH Open Date: 2019-08-02